Ruud de Wildt

Ruud de Wildt has extensive work experience in the biopharmaceutical industry, starting in 1993 as a Ph.D. student at Katholieke Universiteit Nijmegen. After completing their Ph.D., they joined the Medical Research Council as a post-doctoral researcher from 1998 to 2001. Ruud then worked at Domantis as a senior scientist and later as an associate director, managing teams and leading multiple therapeutic and technology programs.

In 2007, Ruud de Wildt joined GlaxoSmithKline (GSK) as a manager and group leader in lead discovery and new technologies. Ruud managed a team of scientists working on various programs in immuno-inflammation and respiratory diseases, as well as technology development. Ruud also served as a program and biology leader for GSK's first inhaled dAb program. Throughout their time at GSK, they held several leadership roles, including head of the pulmonary section and head of lead discovery in Topical BDU, senior director, and ultimately head of lead discovery, director, biopharm R&D.

Currently, Ruud de Wildt is employed at T-Therapeutics Ltd as the VP of Pipeline since May 2023.

Ruud de Wildt has an extensive education history in the field of biochemistry. Ruud pursued a degree in Biochemistry from the Laboratorium School Oss/Nijmegen from 1983 to 1988, obtaining a Technician degree. Ruud then went on to Radboud University, where they completed their Masters in Biomedical Health Science from 1988 to 1992. Ruud further pursued their academic journey at Radboud University, earning a PhD in Biochemistry from 1994 to 1998.